BULLFROG AI HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
BULLFROG AI HOLDINGS, INC. (BFRG) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.50%, a 4.65% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.30%.
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 15.09% decline from fiscal 2024.
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 5.30%, a 20.45% increase from fiscal 2023.
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.40%, a 46.18% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.01%, a 126.32% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.50% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 4.50% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 4.50% 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 5.30% 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 4.40% 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 4.40% 10-K · filed 2025-03-14 | |||
| 2023-09-30 | 4.10% 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | 3.01% 10-K · filed 2023-04-25 | |||
| 2021-12-31 | 1.33% 10-K · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |